Clinical management of osteoporosis in women with a history of breast carcinoma

Cancer

Volumn 104, Issue 3, 2005, Pages 443-456

  Van Poznak, Catherine ^a   Sauter, Nicholas P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant breast carcinoma survivorship; Breast carcinoma; Osteopenia; Osteoporosis

Indexed keywords

ANASTROZOLE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; CLODRONIC ACID; CONJUGATED ESTROGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETIDRONIC ACID; EXEMESTANE; GESTAGEN; GLUCOCORTICOID; GONADORELIN; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

AGING; BONE DISEASE; BONE MASS; BONE STRENGTH; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FRAGILITY FRACTURE; HEALTH CARE ORGANIZATION; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MEDLINE; METABOLIC ACIDOSIS; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SCREENING; UNITED STATES;

ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 22544478433     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21201     Document Type: Review

References (92)

1. American Association of Clinical Endocrinologiste. AACE medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544-564.
2. Raisz, LG, Kream BE, Lorenzo JA. Metabolic bone disease. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky K, editors. Williams textbook of endocrinology, 10th ed. Philadelphia: Saunders, 2003;1373-1410.
3. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-1508.
4. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289:1501-1504.
5. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345-357.
6. Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-FMS and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med. 1999;190:1741-1754.
7. Seeman E. Osteoporosis II: pathogenesis of bone fragility in women and men. Lancet. 2002:359:1841-1850.
8. Dawson-Hughes B, Bonner FJ Jr., Gold DT, et al. (Development Committee). Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, 2003. Available at URL: http//:www.nof.org [accessed November 29, 2004].
9. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-2822.
10. Marwick C. Consensus panel considers osteoporosis. JAMA. 2001;283:2093-2095.
11. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis and therapy (review]. JAMA. 2001;285:785-795.
12. Melton LI, Cooper C. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic Press, 2001:557-567.
13. Cummings S, Melton L. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-1767.
14. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin. 2005;55:10-30.
15. Earle CC, Burstein HJ, Winer EP, et al. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447-1451.
16. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18:1570-1593.
17. Writing Group for the Women's Health Initiative Investigators (WHI). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
18. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
19. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344:276-285.
20. Ganry O, Peng J, Dubreuil A. Is there a reduced risk of breast cancer among women with hip fractures? Eur J Epidemiol. 1999;15:313-315.
21. Cauley JA, Gutai JP, Kuller LH, et al. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol. 1989;129:1120-1131.
22. Vatten LJ, Kvinnsland S. Body mass index and risk of breast cancer. A prospective study of 23,826 Norwegian women. Int J Cancer. 1990;45:440-444.
23. La Vecchia C, Negri E, Franceschi S, et al. Body mass index and post-menopausal breast cancer: an age-specific analysis. Br J Cancer. 1997;75:441-444.
24. Hall HI, Coates RJ, Uhler RJ, et al. Stage of breast cancer in relation to body mass index and bra cup size. Int J Cancer. 1999;82:23-27.
25. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group JAMA. 1996;276:1404-1408.
26. Zmuda JM, Cauley JA, Ljung BM, et al. Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst. 2001;93:930-936.
27. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 1997;336:611-617.
28. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
29. Holmberg L, Anderson H, for the HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453-455.
30. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol. 2003;30:763-775.
31. Love RR, Mazess RR, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852-856.
32. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78-84.
33. Zujewski J, Eng-Wong J, Reynolds J, et al. A Phase 2 trial of raloxifene in premenopausal women at high risk for developing invasive breast cancer (abstract 417]. Breast Cancer Res Treat. 2002;76(Suppl 1):S108.
34. Sverrisdottir A, Fornander T, Jacobsson H, et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22:3694-3699.
35. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365-2370.
36. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res. 2002;7:172-178.
37. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole in healthy postmenopausal women rationale for prevention (abstract 3091]. Proc Am Soc Clin Oncol. 2001;20:3356.
38. Eastell R. Effect of anastrozole (Arimidex) on bone mineral density: 2-year results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial [abstract M070]. J Bone Miner Res. 2003;18(Suppl 2):S312.
39. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431-2442.
40. Gnant M, Jakesz R, Mlineritsch B, et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen-bone density subprotocol results of a randomized multicenter trial (ABCSG-12) [abstract 6]. Breast Cancer Res Treat. 2004;88(Suppl 1):S8-S9.
41. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139.
42. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast-cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802-1810.
43. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
44. Ferrari L, Bajetta E, Martinetti A, et al. Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? Int J Oncol. 2003;22:1081-1089.
45. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
46. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report, 2004. J Clin Oncol. 2005;23:619-629.
47. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974-984.
48. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:930-942.
49. Creep NC, Giuliano AE, Hansen NM, et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med. 2003;114:653-659.
50. Van Poznak CH, Howard JE, Seidman AD, et al. Bone mineral density and hormone receplor status in patients with newly diagnosed breast cancer, a retrospective assessment (abstract 370]. Breast Cancer Res Treat. 2002;76(1 Suppl):S99.
51. Chen Z, Maricic M, Bassford TL, et al. Increased fracture risk among breast cancer survivors-results from the Women's Health Initiative [abstract 1077]. J Bone Miner Res. 2003;18(Suppl 2):S22.
52. Young DM, Fioravanti IL, Olson HM, Prieur DI. Chemical and morphologic alterations of rabbit bone induced by Adriamycin. Calcif Tissue Res. 1975;18:47-63.
53. Wang TM, Shih C. Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. Acta Anat (Basel). 1986;127:93-99.
54. Wheeler DL, Vander Griend RA, Wronski TJ, et al. The short- and long-term effects of methotrexate on the rat skeleton. Bone. 1995;16:215-221.
55. Powles T, Hickish T, Kanis I, et al. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78-84.
56. Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15:955-962.
57. Saarto T, Blomqvist C, Valimaki M, et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75:602-605.
58. Shapiro C, Manola I, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19:3306-3311.
59. Melton JL, Khosla S, Malkasian GD, et al. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res. 2003;18:900-905.
60. Cummings SR, Palerma L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry. JAMA. 2000;283:1318-1321.
61. Hillner BE, Ingle IN, Chlebowski RT, el: al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057.
62. Kanis IA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int. 2000;11:192-202.
63. Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int. 2000;11:76-82.
64. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.
65. Riggs BL, Melton LJ. The prevention and treatment of osteoporosis. N Engl J Med. 1992;327:620-627.
66. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
67. Kannus P, Pakkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med. 2000;343:1506-1362.
68. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
69. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-516.
70. Heikkinen JE, Selander KS, Laitinen K, et al. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res. 1997;12:103-110.
71. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 1997;103:298-307.
72. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
73. Diel I, Jolomayeer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357-363.
74. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19:10-17.
75. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20:3219-3224.
76. Jaschke A, Bastert G, Solomayer EF, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a long time follow-up (abstract). Proceedings ASCO (post-meeting edition). J Clin Oncol. 2004;22(14S):529.
77. Powles T, McCloskey E, Kurkllahti M. Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial (abstract). Proceedings ASCO (post-meeting edition). J Clin Oncol. 2004;22(14S):528.
78. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004;43:650-656.
79. O'Regan RM, Gajdos C, Dardes RC, et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst. 2002;94:274-283.
80. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-276.
81. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
82. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312-321.
83. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with Stage I, II, or III breast cancer. N Engl J Med. 2000;342:525-533.
84. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88:1652-1658.
85. Body JJ, Gaich GA, Wim H, et al. A randomized double-blind trial to compare the efficacy of teriparatide with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:4528-4535.
86. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.
87. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
88. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349:1207-1215.
89. Johnell O, Scheele WH, Lu Y, Reginster J, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:985-992.
90. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. JAMA. 2003;289:2525-2533.
91. Nelson HD, Helfand M, Woolf SH, et al. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:529-541.
92. Brown PJ, Josse RG. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(Suppl 10):S1-S34.